Jeanette Rooney, Cpa, Cgma Email and Phone Number
Jeanette Rooney, Cpa, Cgma work email
- Valid
- Valid
- Valid
- Valid
Jeanette Rooney, Cpa, Cgma personal email
Jeanette Rooney, Cpa, Cgma phone numbers
Offering 30 years in progressive Finance Leadership roles in the global Life Sciences Industry for Fortune 100 elites Johnson & Johnson & Merck, overseeing all aspects of Financial Accounting / Planning / Compliance / Operations for major joint ventures with AstraZeneca, Johnson & Johnson, DuPont; biotech start-ups, Olatec Therapeutics, VaxInnate, Celularity, Cellgorithmics, orphan drug / rare disease companies (Recordatti) and clinical services (Sharp Clinical Services). Recognized as a key contributor with broad accounting & finance experience; strong business acumen. Dedicated to maximizing quality, accuracy & leading with effective & efficient oversight. Quick learner, hands on leader, works well independently or as a key contributor within executive teams; seasoned in building / managing high-value, strategic relationships. Select Career Accomplishments: ◆ Transitioned from public to private sector as a Finance Controller & Consultant for private equity and biotech start-up companies at varying stages of their life cycle. Generated Policies & Procedures, Internal / External Reporting Packages, Long Range Forecast Model, implemented Financial Systems, managed financial operations in addition to cash burn / runway, S-1 preparation & wind-down activities.◆ Managed 25% of Merck’s PTOI during major Joint Ventures with J&J, AstraZeneca & DuPont.◆ Leadership team member tasked with evaluating multi-year strategic decisions for the License & Option Agreement between AZLP & Merck; evaluation attained $2.1B additional income for Merck through 2014.◆ Assisted in attaining a $98.5M judgment as the Corporate 30(b)(6) witness deposed in a patent-infringement case against Apotex’s at-risk launch of generic PRILOSEC®.◆ Negotiated/Executed divestiture of Merck’s 50% ownership in JJMSD Europe/JJMCP US.◆ Evaluated/Executed DuPont trademark agreement, securing ownership of COZAAR®/HYZAAR® marks after agreement expiry.◆ Evaluated Rx-to-OTC switch candidates (MEVACOR®, FLEXERIL®)/executed Authorized Generic Agreements (PRILOSEC®, PLENDIL®, ENTOCORT®, TOPROL®).◆ Key member of Merck’s financial re-engineering/cross-functional team; implemented JD Edwards GL/AR (addressing 100~ system interfaces); SAP conversion.
-
Vice President Finance & TreasurerOlatec Therapeutics Mar 2022 - PresentNew York, New York, UsServing as the financial advisor to the CEO and executive teams, responsible for the oversight of accounting operations, cash management, and for providing timely and accurate financial data to enable strategic decision making about the Organization’s future:• Ensuring an accurate / timely year and month-end close process to include gathering and analyzing financial data, recording financial transactions, preparing account reconciliations, managing accounts payable, payroll and benefits, cash disbursements, cashflow management, and the preparation of financial reports (Balance Sheet, Income Statement, Cash Flow Statement, and other financial models as needed). Prepare quarterly Board Presentations.• Supervise annual audited financial reviews in addition to the annual tax return preparation with external auditors. Maintain partnership ownership schedule, review K-1 tax returns and disbursement of K-1 returns to partners, ensure tax compliance, renew all insurance policies.• Create and maintain the annual budget, periodic forecast updates and other ad hoc requests.• Operate in a mode of continuous improvement and guide / mentor individuals under my supervision.
-
Finance Controller (Interim)Sharp, Part Of Udg Healthcare Oct 2021 - Mar 2022Allentown, Pa, UsAs the Interim Finance Controller, responsibilities included the oversight & management of the accounting and financial reporting activities of the Company, the development & management of the Finance Team, ensuring compliance with US GAAP, IFRS, Parent Company Reporting, & maintaining internal control structure. Executes the annual budget timeline, prepares necessary information to support approval of the annual budget and supplies reports & analysis to functional departments to aid in managing / controlling spending & maintaining profitability. Works with Business Development & Project Management Teams, responsible for maintaining a robust revenue tracking system which monitors actual & forecasted performance. Researches, investigates, establishes and / or recommends improvements and / or different methods of accounting policies & procedures. -
Consultant, Finance - Life Sciences IndustryVaco / Independent Consultant / Solomon Edwards Sep 2017 - Oct 2021Cellgorithmics (Short-Term Assignments for Early-Stage Life Science Start-Ups: Contract) (June 2021 - September 2021)__________Implemented QuickBooks Online, recorded GL activity, developed Financial Statements, Forecast, Board Packages & provided guidance to CEO._________Amneal Pharmaceuticals: (Short-Term Assignment for Vaco) (February 2018 - April 2018)__________Reporting to the Senior Director of Financial Accounting & Reporting, assisted in the preparation of Company's 2018 SEC Filings, Fourth Quarter/Full Year Results, Press Release, Earnings Call Package/Presentation, Quarterly 10Q & the Adoption of ASC 842. Celularity (Short-Term Assignment for Taco) (January 2017 - January 2018)__________Reported directly to EVP Business Development & Corporate Strategy and VP of Finance, worked with business unit owners to create the Budget and Five Year Forecast, prepared financial analyses to update Senior Management, the Audit Committee and the BOD on spending and variances to Budget. Maintained strong rapport with business owners & management throughout the budgeting & forecasting process. Developed business analysis & key analytics to assist in the forecasting of Cash Flows. Developed Company's Financial Policies & Procedures, Internal & External Financial Reporting Packages & Five-Year Forecast Model, consolidated Financial statements, assisted accounting staff in the appropriate application of accounting standards and CFGI in recasting prior financials to conform with GAAP.Recordati Rare Diseases (Short-Term Assignment; September 2017 - November 2017)__________Assisted Finance Organization in a short-term Controllership capacity. Helped Finance Organization fulfill its' third quarter accounting obligations while Assistant Controller focused on annual business plan presentation/submission.
-
Financial Controller (Biotech Start-Up Funded By Barda & Nih)Vaxinnate Corporation Jun 2015 - Aug 2017Leveraged 20+ years in Fortune 100 finance leadership roles to take over diverse projects for Start-up Company such as IPO activities, S-1 Preparation, ensuring GAAP and SOX compliance, enabling SEC Reporting, successfully resolving audits, mentoring accounting personnel, and spearheading GL functions. Accountable directly to the CFO; compiled and presented financial data for annual budget, forecasts, capital plan, month-end, year-end, all scheduled and ad-hoc reports and wind-down activities. Influential in building and maintaining internal financial/accounting infrastructure - control systems, SOPs, transaction-processing operations and policies.Expertly compiled data, verified accuracy and ensured timely reporting for AP/AR, forecasting, treasury functions, capital and expense planning and special projects such as equity financing.Administered high value government contracts (HHS, NIH, BARDA); built strategic relationships within major federal agencies. Streamlined workflow and communication among multiple internal departments and external 3rd parties. Collaborated with business units such as R&D to successfully secure government funding for biomedical research grants.Troubleshot operations to identify areas for improvement; upgraded ADP and QuickBooks. Orchestrated External, Federal and State Governments audits.Thrived within an extremely fast-paced, ever-changing start-up environment via flexibility, willingness to take on any challenge, and proactive leadership strengths. Passed DFAS final audit for closure of contract with BARDA (August 2017) ending in VaxInnate's favor!
-
Director, Alliance Management Finance & Business Development SupportMerck & Co., Inc. 2000 - 2015Managed 25% of Merck’s Pre-Tax Operating Income as the business partner to Merck’s Joint Ventures with Johnson & Johnson, AstraZeneca & DuPont. Utilized strong relationship building & negotiating talents to revitalize key alliances & partnerships that had eroded. Accounted for Merck's multi-billion dollar supply-sales business & JV income. Engaged in budgeting, forecasting, business analysis, strategic plan, consolidated US GAAP financial statements, commentary & analysis, MD&A and footnote disclosures for 10-Q/10-K filings, 8K filings, and fulfilled all reporting requirements ensuring SOX compliance. Orchestrated and resolved external audits for parent company and third party strategic partners ensuring contractual compliance. ◆AstraZeneca/Merck◆Leadership team member tasked with evaluating multi-year strategic decisions related to the License & Option Agreement between AZLP & Merck; renegotiation of 2012 Agreement attained $2.1B incremental operating income for Merck through 2014.Served as the 30(b) (6) Witness in the PRILOSEC® patent infringement case against Apotex: Verdict Awarded: $98.5 Million.Participated on the NEXIUM® Patent Litigation Settlement Team (one of the top-selling drugs of all time). Executed Authorized Generic Agreements (PRILOSEC®, PLENDIL®, ENTOCORT®, TOPROL®).◆Johnson & Johnson/Merck◆Negotiated/executed divestiture of Merck’s 50% interest in JJMSD Europe & JJMCP US.Evaluated internal/external Rx-to-OTC switch candidates including MEVACOR® in the US and Ivermectin for head lice in Europe. ◆Dupont/Merck◆Oversaw Merck’s global relationship with DuPont for the multi-billion dollar products, COZAAR® & HYZAAR®. Accounted for the accuracy of gross to net & gross to contractual sales for the determination of royalties & partnership income.Negotiated/executed Trademark Agreement to secure ownership of COZAAR® & HYZAAR® product marks upon patent & Agreement expiry.
-
Manager, General Accounting; Senior Analyst, Consolidation & Property AccountingMerck & Co., Inc. 1993 - 2000Responsible for the ownership and oversight of US General Ledger and Master Chart of Accounts and the oversight of approximately 20 individuals tasked with maintaining the General Ledger and Chart of Accounts, including monthly and year-end close and year-end roll-over, ensured standard journal entries from each area were posted, financial statements were produced timely and with the highest level of quality and accuracy. Consistently produced reports on time and with the highest levels of quality and accuracy.Analyzed transactions, accounting policies and procedures to advise on best practices; orchestrated and resolved internal and third party audits. Provided input for Headquarters’ 10Q, 10K, MD&A and Financial Footnotes.Selected as a key team member to coordinate divestiture of Merck’s Crop Protection business to Novartis and evaluate contribution of Merck’s Animal Health business to the Rhone Merieux Joint Venture. Provided transitional services to JV (payroll, general ledger).Supervised a staff of ~20 individuals providing on-going coaching, handling disciplinary matters, holding quarterly performance meetings, determining annual performance ratings and completing year-end reviews As the Finance Team Lead, directly accountable for the General Ledger conversion to JD Edwards including the production of timely and accurate financial statements by Functional Area.Selected as a key team member to coordinate divestiture of Merck’s Crop Protection business to Novartis and evaluate contribution of Merck’s Animal Health business to the Rhone Merieux Joint Venture. Provided transitional services to JV (payroll, general ledger)Performed on-campus recruiting, interviewing and hiring at Rutgers and Fairleigh Dickenson for Merck Finance. Supported external auditors in due diligence.
-
AccountantJohnson & Johnson 1988 - 1993New Brunswick, Nj, UsCOST ACCOUNTANT, National Operations AccountingACCOUNTANT, Financial ReportingASSISTANT ACCOUNTANT, Marketing Accounting
Jeanette Rooney, Cpa, Cgma Skills
Jeanette Rooney, Cpa, Cgma Education Details
-
Rutgers Business School(Cum Laude) -
Rutgers UniversityAccounting (Cum Laude)
Frequently Asked Questions about Jeanette Rooney, Cpa, Cgma
What company does Jeanette Rooney, Cpa, Cgma work for?
Jeanette Rooney, Cpa, Cgma works for Olatec Therapeutics
What is Jeanette Rooney, Cpa, Cgma's role at the current company?
Jeanette Rooney, Cpa, Cgma's current role is Vice President Finance & Treasurer, Olatec Therapeutics, Inc..
What is Jeanette Rooney, Cpa, Cgma's email address?
Jeanette Rooney, Cpa, Cgma's email address is je****@****rck.com
What is Jeanette Rooney, Cpa, Cgma's direct phone number?
Jeanette Rooney, Cpa, Cgma's direct phone number is +160986*****
What schools did Jeanette Rooney, Cpa, Cgma attend?
Jeanette Rooney, Cpa, Cgma attended Rutgers Business School, Rutgers University.
What are some of Jeanette Rooney, Cpa, Cgma's interests?
Jeanette Rooney, Cpa, Cgma has interest in Social Services, Children, Civil Rights And Social Action, Education, Environment, Poverty Alleviation, Disaster And Humanitarian Relief, Human Rights, Animal Welfare, Arts And Culture.
What skills is Jeanette Rooney, Cpa, Cgma known for?
Jeanette Rooney, Cpa, Cgma has skills like Accounting, Budgets, Forecasting, Cross Functional Team Leadership, Pharmaceutical Industry, Financial Analysis, Finance, Variance Analysis, Financial Reporting, Management, Sap, Managerial Finance.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial